]>
IRCT20230201057300N1 IRCT 2023-02-15 Iran University of Medical Sciences The Efficacy of Venlafaxine and Duloxetine in Improving Chemotherapy-Induced Neurotoxicity Comparison of the Efficacy of Venlafaxine and Duloxetine in Improving Chemotherapy-Induced Neurotoxicity in Cancer Patients 2018-04-14 anticipated 30 Complete https://irct.ir/trial/68429 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Balanced Balance Randomization. N/A Chemotherapy-Induced Peripheral Neuropathy. Intervention group: The First Group Was Treated With Venlafaxine at 37.5 mg Daily and Increased to 75 mg if The Patient Tolerated. The Second Group Was Treated With Duloxetine at 30 mg Daily and Increased to 60 mg Daily. The Treatment Will Last Up to 10 Weeks.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information.
public Farshid Fardad
No. 77, Shahid kiamoradi Ave., Shahid Shiroudi Blvd., Tonekabon Town
Tonekabon Iran (Islamic Republic of) 4681947170 +98 11 5422 8717 drfardadf@yahoo.com Iran University of Medical Sciences scientific Farshid Fardad
No. 77, Shahid kiamoradi Blvd., Shahid Shiroudi Blvd., Tonekabon Town
Tonekabon Iran (Islamic Republic of) 4681947170 +98 11 5422 8717 drfardadf@yahoo.com Iran University of Medical Sciences Iran (Islamic Republic of) Age 18 to 75 years Incidence of Neuropathy after starting Chemotherapy Cancer Diagnosis Receive Chemotherapy 18 years 75 years Both Having an Underlying Neuropathy Disease such as Diabetes Mellitus Incomplete Treatment Intolerance of the patient due to Drug side effects Death of Patients Treatment - Drugs Intervention group: The First Group Was Treated With Venlafaxine at 37.5 mg Daily and Increased to 75 mg if The Patient Tolerated. The Second Group Was Treated With Duloxetine at 30 mg Daily and Increased to 60 mg Daily. The Treatment Will Last Up to 10 Weeks. Severity of Peripheral Neuropathy. Timepoint: Severity of Peripheral Neuropathy at the Beginning of the study then weekly. Method of measurement: NCI- Common Terminology Criteria for Adverse Event- ver3. Iran University of Medical Sciences Approved 2017-05-28 Ethics committee of Iran University of Medicsl Sciences No. 77, Shahid kismoradi Ave., Shahid Shiroudi Blvd., Tonekabon Town Tonekabon Mazandaran Iran (Islamic Republic of)